Which medications in the drug class Antineoplastics, BRAF Kinase Inhibitors are used in the treatment of Non-Small Cell Lung Cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

Antineoplastics, BRAF Kinase Inhibitors

BRAF genes direct protein production which induces signal transmission along the RAS/MAPK pathway. RAS/MAPK pathway regulates cell growth, cell differentiation, cell migration, and apoptosis. BRAF mutations can cause dysregulation of cell growth resulting in tumor progression [233]

Dabrafenib (Tafinlar)

Dabrafenib selectively inhibits multiple mutated BRAF kinases, BRAF V600E, BRAF V600K, and BRAF V600D. BRAF kinase inhibition primarily stunts cells growth. The combination with trametinib targets two different kinases in the RAS/ MEK pathway causing greater growth inhibition of BRAF V600 mutation.  


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!